Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis

Roy Gerona, Anita Wen, Aaron T Chin, Catherine A Koss, Peter Bacchetti, John Metcalfe, Monica Gandhi, Roy Gerona, Anita Wen, Aaron T Chin, Catherine A Koss, Peter Bacchetti, John Metcalfe, Monica Gandhi

Abstract

Background: Tuberculosis (TB) is the leading cause of death from an infectious pathogen worldwide and the most prevalent opportunistic infection in people living with HIV. Isoniazid preventive therapy (IPT) reduces the incidence of active TB and reduces morbidity and mortality in HIV-infected patients independently of antiretroviral therapy. However, treatment of latent or active TB is lengthy and inter-patient variability in pharmacokinetics and adherence common. Current methods of assessing adherence to TB treatment using drug levels in plasma or urine assess short-term exposure and pose logistical challenges. Drug concentrations in hair assess long-term exposure and have demonstrated pharmacodynamic relevance in HIV.

Methods: A large hair sample from a patient with active TB was obtained for assay development. Methods to pulverize hair and extract isoniazid were optimized and then the drug detected by liquid chromatography/ tandem mass spectrometry (LC/MS-MS). The method was validated for specificity, accuracy, precision, recovery, linearity and stability to establish the assay's suitability for therapeutic drug monitoring (TDM). Hair samples from patients on directly-observe isoniazid-based latent or active TB therapy from the San Francisco Department of Public Health TB clinic were then tested.

Results: Our LC/MS-MS-based assay detected isoniazid in quantities as low as 0.02ng/mg using 10-25 strands hair. Concentrations in spiked samples demonstrated linearity from 0.05-50ng/mg. Assay precision and accuracy for spiked quality-control samples were high, with an overall recovery rate of 79.5%. In 18 patients with latent or active TB on treatment, isoniazid was detected across a wide linear dynamic range.

Conclusions: An LC-MS/MS-based assay to quantify isoniazid levels in hair with performance characteristics suitable for TDM was developed and validated. Hair concentrations of isoniazid assess long-term exposure and may be useful for monitoring adherence to latent or active TB treatment in the setting of HIV.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Representative extracted ion chromatogram of…
Fig 1. Representative extracted ion chromatogram of INH in small hair samples from a patient on INH (A) and a patient not taking INH (B).
Fig 2. INH concentrations in 18 hair…
Fig 2. INH concentrations in 18 hair samples from patients recruited from the San Francisco Department of Public Health TB Clinic (11 with active TB; 7 with latent TB).

References

    1. World Health Organization. Global tuberculosis report 2015. Available at . Accessed on January 6, 2016.
    1. Group TAS, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015,373:808–822. 10.1056/NEJMoa1507198
    1. Hosseinipour M, Bisson G, Miyahara S, Sun X, Moses A, Riviere C, et al. Empiric TB therapy does not decrease early mortality compared to isoniazid preventive therapy in adults with advanced HIV initiating ART: results of ACTG A5274 (REMEMBER study). 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), Vancouver, Canada, 19–22 July 2015 (abstract MOAB0205LB).
    1. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011,204:1951–1959. 10.1093/infdis/jir658
    1. Egelund EF, Peloquin CA. Editorial commentary: pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance. Clin Infect Dis 2012,55:178–179. 10.1093/cid/cis366
    1. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002,62:2169–2183.
    1. Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update. Clin Infect Dis 2010,50:1377–1386. 10.1086/652147
    1. Tesfahuneygn G, Medhin G, Legesse M. Adherence to Anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia. BMC Res Notes 2015,8:503 10.1186/s13104-015-1452-x
    1. Wiltshire CS, Lamorde M, Scherrer A, Musaazi J, Corti N, Allan B, et al. Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda. J Int AIDS Soc 2014,17:19585 10.7448/IAS.17.4.19585
    1. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009,48:1685–1694. 10.1086/599040
    1. Alffenaar JW. Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs. J Infect Dis 2012,205:1765–1766; author reply 1766. 10.1093/infdis/jis270
    1. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 2009,31:327–336. 10.1097/FTD.0b013e31819e91ce
    1. Beumer J, Bosman I, Maes R. Hair as a biological specimen for therapeutic drug monitoring. In J Clin Pract 2001,55:353–357.
    1. Gandhi M, Greenblatt RM. Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern Med 2002,137:696–697.
    1. Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS 2009,23:471–478. 10.1097/QAD.0b013e328325a4a9
    1. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis 2011,52:1267–1275. 10.1093/cid/cir131
    1. van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, et al. Low lopinavir plasma or hair concentrations explain second line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011,56:333–339. 10.1097/QAI.0b013e31820dc0cc
    1. Baxi SM, Greenblatt RM, Bacchetti P, Jin C, French AL, Keller MJ, et al. Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients. PLoS One 2015,10:e0129100 10.1371/journal.pone.0129100
    1. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, et al. Hair and Plasma Data Show That Lopinavir, Ritonavir, and Efavirenz All Transfer From Mother to Infant In Utero, But Only Efavirenz Transfers via Breastfeeding. J Acquir Immune Defic Syndr 2013,63:578–584. 10.1097/QAI.0b013e31829c48ad
    1. Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anastos K, et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis 2012,206:1453–1461. 10.1093/infdis/jis508
    1. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, et al. Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). PLoS One 2014,9:e83736 10.1371/journal.pone.0083736
    1. Hickey MD, Salmen CR, Tessler RA, Omollo D, Bacchetti P, Magerenge R, et al. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr 2014,66:311–315. 10.1097/QAI.0000000000000154
    1. Koss C, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, et al. Hair Concentrations of Antiretrovirals Predict Viral Suppression in HIV-Infected Pregnant and Breastfeeding Ugandan Women. AIDS 2015,29:825–830. 10.1097/QAD.0000000000000619
    1. Prasitsuebsai W, Kerr SJ, Truong KH, Ananworanich J, Do VC, Nguyen LV, et al. Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children. AIDS Res Hum Retroviruses 2015,31:1009–1014. 10.1089/AID.2015.0111
    1. Gandhi M, Yang Q, Bacchetti P, Huang Y. Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings. AIDS Res Hum Retroviruses 2014,30:25–28. 10.1089/AID.2013.0239
    1. Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, et al. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. J Infect Dis 2015,212:1402–1406. 10.1093/infdis/jiv239
    1. Eisenhut M, Thieme D, Schmid D, Fieseler S, Sachs H. Hair Analysis for Determination of Isoniazid Concentrations and Acetylator Phenotype during Antituberculous Treatment. Tuberc Res Treat 2012,2012:327027 10.1155/2012/327027
    1. Chen X, Song B, Jiang H, Yu K, Zhong D. A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of isoniazid and ethambutol in human plasma. Rapid Commun Mass Spectrom 2005,19:2591–2596.
    1. Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009,877:285–290. 10.1016/j.jchromb.2008.12.024
    1. Song SH, Jun SH, Park KU, Yoon Y, Lee JH, Kim JQ, et al. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007,21:1331–1338.
    1. Kim HJ, Seo KA, Kim HM, Jeong ES, Ghim JL, Lee SH, et al. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry. J Pharm Biomed Anal 2015,102:9–16. 10.1016/j.jpba.2014.08.026
    1. DiFrancesco R, Tooley K, Rosenkranz SL, Siminski S, Taylor CR, Pande P, et al. Clinical pharmacology quality assurance for HIV and related infectious diseases research. Clin Pharmacol Ther 2013,93:479–482. 10.1038/clpt.2013.62
    1. FDA. Guidance for Industry Bioanalytical Method Validation. 2013. Found at
    1. Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 2007,63:633–639.
    1. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003,167:1341–1347.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe